Articles Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers SABRCOMET a randomised phase 2 openlabel trial

[Articles] Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial

19:39 EDT 11 Apr 2019 | The Lancet

SABR was associated with an improvement in overall survival, meeting the primary endpoint of this trial, but three (4·5%) of 66 patients in the SABR group had treatment-related death. Phase 3 trials are needed to conclusively show an overall survival benefit, and to determine the maximum number of metastatic lesions wherein SABR provides a benefit.

More From BioPortfolio on "[Articles] Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial"